Previous studies reported colorectal cancer diagnosis using serum CEA, AFP, and CA19-9, achieving sensitivities of 80.43%, 73.91%, and 69.57%, and specificities of 75.00%, 69.44%, and 61.11%, respectively (41). This evidence concerns the gene CEACAM5 and colorectal cancer.